Navigation Links
Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
Date:6/28/2012

(PRWEB) June 28, 2012

ProImmune's Immune Formulation 200® is able to potentiate Glutathione synthesis via the Pleiotropic Paradox, which utilizes the pleiotropic delivery system of the disulfide bond--L-Cystine--to carry L-Cysteine safely to cells,. Upon contact with epithelial cells, the L-Cystine is decoupled by the substrate specific enzyme thioltransferase, allowing L-Cysteine safely into cells to enter into the Glutathione Synthesis chain.

Dr. Albert Crum, a Harvard-trained scientist and CEO of The ProImmune Company, LLC, Rhinebeck (NY) is the inventor of Patent RE42,645E/RE39,734 and its Immune Formulation 200®. University research using Immune Formulation 200® provided by The ProImmune Company, LLC, has demonstrated that this novel Glutathione precursor’s immune support effects are unexpectedly wide-ranging.

The coupling of a thiol-disulfide compound is another safe physiological carrier system for L-Cysteine, because it holds the high oxidizability of L-Cysteine in abeyance ("on hold") until it is delivered to the intracellular milieu.

Metaphorically speaking, the Glutathione pathway of Immune Formulation 200® activates the immune system like a city power grid station which ignites or electrifies a city's lights. The Dietary Supplement Immune Formulation 200® is a strong support for the immune system in multiple ways.

Immune Formulation 200® works physiologically, both to raise bodily Glutathione levels and to activate Nrf2, while offering an inherently natural sweet taste without carbohydrates. Immune Formulation 200® (“F1”), a dietary supplement, is the patented precursor for the intracellular synthesis of Glutathione.

Specifically, research on Immune Formulation 200® provided by The ProImmune Company, L.L.C., has been conducted over several years by a team at Drew University of Medicine & Science, Los Angeles (CA). Other universities such as UCLA, University of California (Irvine), Los Angeles Biomedical Research Institute (Torrance CA), and University of Texas Southwestern (Dallas) are included among those conducting the basic research on Immune Formulation 200®. Research results began being published in 2008. Research studies of Immune Formulation 200® have pointed to the interrelationship between Glutathione repletion and activation of gene Nrf2.

Immune Formulation 200® is winning international consumer favor--for the value of its diversified immunological support and for its naturally sweet taste.

The study which associated Immune Formulation 200® with the activation of Nrf2 was supported by NIH-NCCR Accelerating Excellence in Translation Science Grant (U54 RR026138) and NIH-NIMHDP20MD00182.

© 2012 The ProImmune Company LLC

Read the full story at http://www.prweb.com/releases/2012/6/prweb9653539.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
2. Study improves understanding of surface molecules in controlling size of gold nanoparticles
3. Nanoparticles found in moon glass bubbles explain weird lunar soil behavior
4. Nanoparticles seen as artificial atoms
5. Exotic particles, chilled and trapped, form giant matter wave
6. A milestone in nanoparticle research: Nanoparticle test handbook sets the standards
7. Genesis Biopharma Mentioned Favorably in BioMedReports Article
8. Light touch keeps a grip on delicate nanoparticles
9. New technique uses electrons to map nanoparticle atomic structures
10. New measuring techniques can improve efficiency, safety of nanoparticles
11. Metal nanoparticles shine with customizable color
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
(Date:5/2/2016)... , May 2, 2016 ... that its technology partner Mannin Research Inc. will be ... (ARVO), which takes place from May 1-5, 2016 in ... will be meeting with its vendors and research partners. ... business development goals and other collaborative opportunities for the ...
(Date:5/2/2016)... ... , ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher of remote ... modules to its flagship X-Win32 PC X server. The new modules enable X-Win32 ... PC over encrypted SSH. , Traditionally, users of PC X servers deploy the XDMCP ...
(Date:4/29/2016)... , ... April 30, 2016 , ... The MIT bioLogic ... design, the bioLogic team explored how bacterial properties can be applied to fabric and ... Natto bacteria, which move in response to humidity change. The team harvested Natto cells ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., ... surgical procedures, today announced the completion of a significant transaction and partnership that ... future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):